Kane Biotech Inc., a Winnipeg-based biotechnology company specializing in advanced wound care solutions, has announced significant expansion of its U.S. commercial operations through strategic partnerships and sales team development. The company revealed these moves as part of its broader strategy to establish nationwide presence for its revyve® Antimicrobial Wound Gel product line.
Strategic Government Distribution Partnership
The company has entered into a distribution agreement with Marathon Medical Corporation, a federally verified Service-Disabled Veteran-Owned Small Business that serves as a leading nationwide medical supply distributor. Marathon maintains an extensive portfolio of federal procurement contracts that position the company as a key partner within the U.S. Veterans Affairs, Department of Defense, and Indian Health Services healthcare supply chains.
This partnership provides Kane Biotech with access to established U.S. government-authorized purchasing pathways, significantly streamlining procurement, logistics, and product onboarding processes for the revyve wound care line. Marathon's national distribution capabilities, decades of experience serving federal healthcare agencies, and veteran-owned status are expected to meaningfully reduce market entry barriers for Kane's products.
Enhanced Market Access
Through this collaboration, Kane strengthens its ability to penetrate and scale within the U.S. healthcare system, ensuring veterans, DOD service members, indigenous peoples and their healthcare providers can more easily access innovative wound care solutions. The partnership represents a critical step in making revyve products available through government healthcare channels that serve millions of Americans.
Sales Team Expansion
Concurrently, Kane Biotech has commenced building a contract-based sales team with representatives already in place across various U.S. regions. The company plans to continue expanding this group throughout 2026, creating a geographically diverse network of experienced sales professionals.
This expansion initiative marks a key milestone in Kane's broader strategy to establish a scalable, multi-channel U.S. distribution infrastructure. By developing a robust national sales foundation, the company aims to increase brand presence, enhance customer engagement, and accelerate access to the revyve product line for clinicians across the country.
Leadership Perspective
"We are continuing to strategically build the commercial infrastructure required to make revyve a national brand in advanced wound care," said Interim CEO Dr. Robert Huizinga. "Our new contract-based sales agents expand our reach into key markets, while our partnership with Marathon Medical gives us a powerful foothold within the U.S. government system—an essential step in making revyve accessible to the veterans, active service members and indigenous peoples who need these innovative solutions."
Regulatory Status and Product Portfolio
Kane Biotech's revyve Antimicrobial Wound Gel has received U.S. FDA 510(k) clearance and Health Canada approval, with the company offering three FDA-cleared and two Health Canada-approved formats of their advanced wound care products. The company's technology represents a significant advancement in wound care management, addressing critical needs in infection prevention and wound healing.
The strategic moves announced position Kane Biotech for accelerated growth in the substantial U.S. wound care market, leveraging both government healthcare channels and traditional commercial pathways to maximize product accessibility and adoption across diverse healthcare settings.
